109 related articles for article (PubMed ID: 23803125)
1. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival.
Nonsrijun N; Mitchai J; Brown K; Leksomboon R; Tuamsuk P
Asian Pac J Cancer Prev; 2013; 14(5):3331-5. PubMed ID: 23803125
[TBL] [Abstract][Full Text] [Related]
2. Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Ok Atılgan A; Özdemir BH; Yılmaz Akçay E; Tepeoğlu M; Börcek P; Dirim A
Ann Diagn Pathol; 2020 Apr; 45():151480. PubMed ID: 32106037
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
4. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
5. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.
Mehta PB; Jenkins BL; McCarthy L; Thilak L; Robson CN; Neal DE; Leung HY
Oncogene; 2003 Mar; 22(9):1381-9. PubMed ID: 12618764
[TBL] [Abstract][Full Text] [Related]
6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
7. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Microvascular Density and Matrix Metalloproteinase 11 Expression in Prostate Cancer Tissues: a Preliminary Study in Thailand.
Kanharat N; Tuamsuk P
Asian Pac J Cancer Prev; 2015; 16(15):6639-43. PubMed ID: 26434888
[TBL] [Abstract][Full Text] [Related]
9. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.
Silva MM; Matheus WE; Garcia PV; Stopiglia RM; Billis A; Ferreira U; Fávaro WJ
Int Braz J Urol; 2015; 41(5):849-58. PubMed ID: 26689510
[TBL] [Abstract][Full Text] [Related]
10. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
McDonald ML; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Freedland SJ; Kane CJ
Urol Oncol; 2018 May; 36(5):239.e17-239.e25. PubMed ID: 29429895
[TBL] [Abstract][Full Text] [Related]
11. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
13. Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer.
Reis ST; Viana NI; Iscaife A; Pontes-Junior J; Dip N; Antunes AA; Guimarães VR; Santana I; Nahas WC; Srougi M; Leite KR
Int Braz J Urol; 2015; 41(6):1088-95. PubMed ID: 26742965
[TBL] [Abstract][Full Text] [Related]
14. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy.
Rabien A; Fritzsche FR; Jung M; Tölle A; Diamandis EP; Miller K; Jung K; Kristiansen G; Stephan C
Int J Cancer; 2010 Nov; 127(10):2386-94. PubMed ID: 20473923
[TBL] [Abstract][Full Text] [Related]
15. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.
Babichenko II; Andriukhin MI; Pulbere S; Loktev A
Int J Clin Exp Pathol; 2014; 7(12):9090-8. PubMed ID: 25674294
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
[TBL] [Abstract][Full Text] [Related]
18. Presence of high grade tertiary Gleason pattern upgrades the Gleason sum score and is inversely associated with biochemical recurrence-free survival.
Turker P; Bas E; Bozkurt S; Günlüsoy B; Sezgin A; Postacı H; Turkeri L
Urol Oncol; 2013 Jan; 31(1):93-8. PubMed ID: 21316989
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
